Alivus Life Sciences - ALIVUS, 543322 corporate action history

Alivus Life Sciences Ltd. NSE: ALIVUS | BSE: 543322

Mid-range Performer

Download real time

900.90 -6.30 (-0.69%)

27.99% Fall from 52W High

30,512

NSE+BSE Volume

NSE 29 Dec, 2025 2:36 PM (IST)

Alivus Life Sciences Bonus history

Alivus Life Sciences has not announced any bonus since Jan 1, 2000.

See all forthcoming Bonus and Splits

Alivus Life Sciences Split history

Alivus Life Sciences has not split the face value of the share since Jan 1, 2000.

See all forthcoming Bonus and Splits

Dividend history for Alivus Life Sciences

Alivus Life Sciences has declared 5 dividends since Nov. 22, 2021.

In the past 12 months, Alivus Life Sciences has declared an equity dividend amounting to ₹5.00 per share.

At the current share price of ₹900.9000, Alivus Life Sciences's dividend yield is 0.56%.

Ex-Date	Dividend Amount	Dividend Type	Record Date	Instrument Type
01 Sep 2025	5.00	FINAL	01 Sep 2025	Equity Share
17 Oct 2023	22.50	INTERIM	17 Oct 2023	Equity Share
24 Mar 2023	21.00	INTERIM	24 Mar 2023	Equity Share
15 Sep 2022	10.50	FINAL	-	Equity Share
22 Nov 2021	10.50	INTERIM	23 Nov 2021	Equity Share

See all forthcoming dividends Check out stocks with top dividend.

Board Meetings - Alivus Life Sciences

The latest board meeting for Alivus Life Sciences took place on 06 Nov 2025, for the purpose of Quarterly Results

Ex-Date	Purpose	Notes
06 Nov 2025	Quarterly Results	-
01 Aug 2025	Quarterly Results	-
15 May 2025	Audited Results & Final Dividend	-
23 Jan 2025	Quarterly Results	-
24 Oct 2024	Quarterly Results	-
25 Jul 2024	Quarterly Results	-
25 Apr 2024	Audited Results	-
23 Jan 2024	Quarterly Results	-
20 Oct 2023	Quarterly Results	-
09 Oct 2023	Interim Dividend	-

See all Board Meetings for Alivus Life Sciences

Alivus Life Sciences Rights history

Alivus Life Sciences has not issued any rights since Jan 1, 2000.

See all Rights History for Alivus Life Sciences

VOTE: Is Glenmark Life Sciences Ltd. worth buying?

133 Votes:

Buy 75.19%

Sell 12.03%

Hold 12.78%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >